AIMS: The prognostic role of tricuspid regurgitation (TR) associated with organic left-sided valvular heart disease is well known. However, no data are available regarding the prognostic value of functional TR (FTR) in patients with functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction. The purpose of this study was to evaluate the prognostic role of FTR for occurrence of heart failure (HF) and mortality in patients with FMR. METHODS AND RESULTS: We enrolled 373 consecutive patients (mean age 68±11 years) with LV dysfunction and at least mild FMR and with or without FTR, both quantitated by echocardiography. The median follow-up was 32 months (range 1-120 months); 132 (35.4%) and 97 patients developed HF or died, respectively. The incidence of HF at 3 and 6 years was 36±2% and 55±4%, respectively. Moderate to severe FTR [hazard ratio (HR) 1.4, 95% confidence interval (CI) 1.1-2.1, P = 0.01) was an independent determinant of HF. The incidence of HF was 41±5, 46±7, 57±7, and 65±8% for patients without, and with mild, moderate, and severe FTR respectively (P = 0.03). At 3 and 6 years the survival free of all-cause mortality was 77.5±2% and 60±3%, respectively. Moderate to severe FTR (HR 1.6, 95% CI 1.2-2.1, P = 0.01) was an independent determinant of overall mortality. At 6 years, survival free of all-cause mortality was 69±2.5, 67±2.1, 51±2.5, and 40±4.8% for patients without, and with mild, moderate, and severe FTR, respectively (P = 0.004). CONCLUSIONS: Moderate or more FTR is independently associated with worse survival and a high incidence of HF episodes in patients with FMR.
AIMS: The prognostic role of tricuspid regurgitation (TR) associated with organic left-sided valvular heart disease is well known. However, no data are available regarding the prognostic value of functional TR (FTR) in patients with functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction. The purpose of this study was to evaluate the prognostic role of FTR for occurrence of heart failure (HF) and mortality in patients with FMR. METHODS AND RESULTS: We enrolled 373 consecutive patients (mean age 68±11 years) with LV dysfunction and at least mild FMR and with or without FTR, both quantitated by echocardiography. The median follow-up was 32 months (range 1-120 months); 132 (35.4%) and 97 patients developed HF or died, respectively. The incidence of HF at 3 and 6 years was 36±2% and 55±4%, respectively. Moderate to severe FTR [hazard ratio (HR) 1.4, 95% confidence interval (CI) 1.1-2.1, P = 0.01) was an independent determinant of HF. The incidence of HF was 41±5, 46±7, 57±7, and 65±8% for patients without, and with mild, moderate, and severe FTR respectively (P = 0.03). At 3 and 6 years the survival free of all-cause mortality was 77.5±2% and 60±3%, respectively. Moderate to severe FTR (HR 1.6, 95% CI 1.2-2.1, P = 0.01) was an independent determinant of overall mortality. At 6 years, survival free of all-cause mortality was 69±2.5, 67±2.1, 51±2.5, and 40±4.8% for patients without, and with mild, moderate, and severe FTR, respectively (P = 0.004). CONCLUSIONS: Moderate or more FTR is independently associated with worse survival and a high incidence of HF episodes in patients with FMR.
Authors: Toby Rogers; Kanishka Ratnayaka; Merdim Sonmez; Dominique N Franson; William H Schenke; Jonathan R Mazal; Ozgur Kocaturk; Marcus Y Chen; Anthony Z Faranesh; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2015-02-18 Impact factor: 11.195
Authors: Henrike Arfsten; Philipp E Bartko; Noemi Pavo; Gregor Heitzinger; Julia Mascherbauer; Christian Hengstenberg; Martin Hülsmann; Georg Goliasch Journal: Eur J Clin Invest Date: 2019-10-09 Impact factor: 4.686
Authors: Jonas Pausch; Oliver Bhadra; Julian Mersmann; Lenard Conradi; Bjoern Sill; Markus J Barten; Hermann Reichenspurner; Alexander M Bernhardt Journal: J Cardiothorac Surg Date: 2022-02-25 Impact factor: 1.637
Authors: Koki Nakanishi; Shunichi Homma; Jiho Han; Hiroo Takayama; Paolo C Colombo; Melana Yuzefpolskaya; Arthur R Garan; Maryjane A Farr; Paul Kurlansky; Marco R Di Tullio; Yoshifumi Naka; Koji Takeda Journal: J Am Heart Assoc Date: 2018-06-24 Impact factor: 5.501